| Literature DB >> 24039715 |
Niklaus Denier1, Hana Gerber, Marc Vogel, Markus Klarhöfer, Anita Riecher-Rossler, Gerhard A Wiesbeck, Undine E Lang, Stefan Borgwardt, Marc Walter.
Abstract
Heroin dependence is a chronic relapsing brain disorder, characterized by the compulsion to seek and use heroin. Heroin itself has a strong potential to produce subjective experiences characterized by intense euphoria, relaxation and release from craving. The neurofunctional foundations of these perceived effects are not well known. In this study, we have used pharmacological magnetic resonance imaging (phMRI) in 15 heroin-dependent patients from a stable heroin-assisted treatment program to observe the steady state effects of heroin (60 min after administration). Patients were scanned in a cross-over and placebo controlled design. They received an injection of their regular dose of heroin or saline (placebo) before or after the scan. As phMRI method, we used a pulsed arterial spin labeling (ASL) sequence based on a flow-sensitive alternating inversion recovery (FAIR) spin labeling scheme combined with a single-shot 3D GRASE (gradient-spin echo) readout on a 3 Tesla scanner. Analysis was performed with Statistical Parametric Mapping (SPM 8), using a general linear model for whole brain comparison between the heroin and placebo conditions. We found that compared to placebo, heroin was associated with reduced perfusion in the left anterior cingulate cortex (ACC), the left medial prefrontal cortex (mPFC) and in the insula (both hemispheres). Analysis of extracted perfusion values indicate strong effect sizes and no gender related differences. Reduced perfusion in these brain areas may indicate self- and emotional regulation effects of heroin in maintenance treatment.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24039715 PMCID: PMC3769358 DOI: 10.1371/journal.pone.0071461
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Overview of preprocessing steps at the subject level (SPM8).
BIN: Binarization; CSF: Cerebrospinal fluid; GM: Gray matter; WM: White matter.
Socio-demographic and diagnostic characteristics of the study sample.
| Measurements | Subjects (n = 15) |
| Age (years), mean (SD) | 40.9 (6.6) |
| Male gender, n (%) | 9 (60.0) |
| Partnership, n (%) | 6 (40.0) |
| Employment, n (%) | 7 (46.7) |
| Age at first heroin use (years), mean (SD) | 18.1 (3.0) |
| Duration of heroin dependence (years), mean (SD) | 20.5 (7.7) |
| Duration of heroin maintenance (years), mean (SD) | 7.0 (3.9) |
| Heroin dose (mg/day), mean (SD) | 346.0 (173.4) |
| Methadone substitution, n (%) | 5 (33.3) |
| Methadone dose (mg/day), mean (SD) | 30.0 (10.0) |
| Cocaine use, n (%) | 7 (46.7) |
| Cannabis use, n (%) | 4 (26.7) |
| Tobacco use, n (%) | 15 (100.0) |
SD: Standard deviation.
Figure 2Physiological parameters after heroin and placebo administration.
BP: Blood pressure; **: p<0.01.
Psychological effects of heroin.
| Measurements | Placebo | Heroin | p-value |
| HCQ: Desire to use heroin, mean (SD) | 3.6 (0 to 14.5) | 3.9 (0 to 15) | .849 |
| HCQ: Intensions and plans to use heroin, mean (SD) | 2.2 (0 to 9) | 3.1 (0 to 9.5) | .005 |
| HCQ: Anticipation of positive outcome, mean (SD) | 1.4 (0 to 6) | 3.0 (0 to 14) | .056 |
| HCQ: Relief from withdrawal/dysphoria, mean (SD) | 1.0 (0 to 4) | 3.1 (0 to 9) | .047 |
| HCQ: Lack of control over use, mean (SD) | 3.3 (0 to 15) | 2.0 (0 to 11.5) | .128 |
| VAS: Intoxication, mean (SD) | 1.1 (1.7) | 3.7 (2.1) | .005 |
| VAS: Sedation, mean (SD) | 1.7 (2.3) | 3.3 (2.8) | .009 |
| VAS: Withdrawal, mean (SD) | 3.7 (3.0) | 0.4 (1.3) | .001 |
| VAS: Drug effect, mean (SD) | 0.3 (1.0) | 6.5 (2.9) | <.001 |
HCQ: Heroin Craving Questionnaire; SaO2: Blood oxygen saturation; SD: Standard deviation; VAS: Visual Analogue Scale;
: p<0.05.
Effects of heroin on brain perfusion in contrast to placebo.
| Area | Hemisphere | Talairach coordinates of | Cluster size | Cluster p-value | Cluster p-value |
| cluster maximum (x y z) | (voxels) | (uncorrected) | (FWE corrected) | ||
|
| |||||
| Insula (BA 13) | L | −38 3 −9 | 4590 | <.001 | <0.001 |
| Superior Temporal Gyrus (BA 38) | L | −53 15 −11 | |||
| Insula (BA 13) | L | −30 17 −8 | |||
| Anterior Cingulate (BA 24) | R | 8 33 8 | 2664 | <.001 | <0.001 |
| Medial Frontal Gyrus (BA 11) | L | −2 50 −11 | |||
| Anterior Cingulate (BA 24) | R | 8 23 23 | |||
| Precentral Gyrus (BA 44) | R | 63 10 11 | 1379 | 0.001 | 0.026 |
| Insula (BA 13) | R | 36 13 −4 | |||
| Insula (BA 13) | R | 40 4 −4 | |||
|
| |||||
| None | |||||
BA: Brodmann area; L: left; P: perfusion; R: right; WM: white matter;
: p≤0.05;
: p≤0.001.
Each coordinate triple is a peak area of contrast intensity in one of the two significant clusters and refers to a specific area defined in the atlas of Talairach & Tournoux (1988).
Figure 3Altered regional perfusion in heroin in comparison to placebo condition.
A) Relative hypo- (blue) and hyperperfusion (red) in heroin condition projected on an inflated brain (threshold: p<0.05). Hyperperfusion was not significant. B) Significant hypoperfusion (blue) in heroin condition (threshold: p<0.01; FEW corrected p<0.05). The z coordinate shows the position of each slice in reference to the Talairach atlas (see Table 3). The medial prefrontal cortex, the anterior cingulate cortex, and the insular cortex are shown in different colors, in order to clarify the spatial relationship to the significant clusters.
Regional perfusion values of significant clusters.
| Region | Placebo | Heroin | Effect size |
| (Mean/SD/CI 95%) | (Mean/SD/CI 95%) | (Cohen's d) | |
| Cluster 1: left Insula | 97.07/10.93/91–103 | 82.10/10.68/73–88 | 1.38 |
| Cluster 2: right Insula | 79.17/11.03/73–85 | 69.44/12.38/63–76 | 0.82 |
| Cluster 3: ACC/MPFC | 108.71/16.72/99–118 | 92.16/19.0/82–103 | 0.93 |
ACC: Anterior cingulate cortex; CI: Confidence interval; MPFC: Medial prefrontal cortex.